The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
Journal of Korean Medical Science
; : 612-616, 2015.
Article
ي En
| WPRIM
| ID: wpr-99845
المكتبة المسؤولة:
WPRO
ABSTRACT
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the open-label, prospective cohort study to assess the immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 2-dose primary series was given with a 12-month interval. Neutralizing antibody titers were measured before and after each vaccination, and active monitoring for adverse events was performed. After the first dose, 91.1% of subjects had seroprotection with a geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, and GMT showed an increase of 6.5-fold. Most adverse events following immunization were self-limited, and no serious adverse events were reported until 42 days after each dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared to be highly immunogenic and safe.
Key words
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
Vaccines, Attenuated
/
Prospective Studies
/
Cohort Studies
/
Vaccination
/
Encephalitis, Japanese
/
Japanese Encephalitis Vaccines
/
Antibodies, Neutralizing
/
Antibodies, Viral
/
Antibody Formation
نوع الدراسة:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
المحددات:
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
اللغة:
En
مجلة:
Journal of Korean Medical Science
السنة:
2015
نوع:
Article